Publication Details
Abstract
Autoimmune and inflammatory diseases represent a significant global health burden, characterized by dysregulated immune responses that target the body’s own tissues. Recent advances in immunotherapy have revolutionized the management of these disorders, offering more precise and effective treatment strategies. Biological agents, such as monoclonal antibodies targeting tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-17 (IL-17), have significantly improved outcomes in conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Additionally, therapies modulating T-cell activity, such as abatacept and anti-CD20 therapies like rituximab, have shown efficacy in systemic lupus erythematosus and multiple sclerosis. The emergence of Janus kinase (JAK) inhibitors represents another promising advancement, providing oral options that disrupt intracellular signaling pathways involved in immune activation. Furthermore, tolerogenic vaccines and antigen-specific immunotherapies are being explored to re-educate the immune system and promote immune tolerance. Cellular therapies, including regulatory T cell (Treg) expansion and mesenchymal stem cell transplantation, also hold potential for long-term immune modulation. While these innovations mark a significant leap forward, challenges remain, including the risk of infections, high costs, and variable patient responses. Personalized medicine approaches, integrating genetic, immunological, and clinical data, are expected to refine treatment selection and improve efficacy. In conclusion, recent developments in immunotherapy offer new hope for patients with autoimmune and inflammatory diseases, moving toward targeted, individualized care that aims not only to control symptoms but also to modify disease progression and restore immune balance.